365530-10-5

Basic information

• Product Name: 1H-Pyrazole, 5-(4-methylphenyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-
• CAS NO: 365530-10-5
• Molecular Formula: C17H12F3N3O2
• Molecular Weight: 347.296
• Mol File: 365530-10-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazole, 5-(4-methylphenyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole, 5-(4-methylphenyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-(365530-10-5)
• EPA Substance Registry System: 1H-Pyrazole, 5-(4-methylphenyl)-1-(4-nitrophenyl)-3-(trifluoromethyl)-(365530-10-5)

Safety Data

• Hazardous Substances Data: 365530-10-5(Hazardous Substances Data)

Upstream product

• 122-00-9 para-methylacetophenone 
• 720-94-5 4,4,4-trifluoro-1-(4-methylphenyl)butane-1,3-dione 
• 100-16-3 4-nitrophenylhydrazone 

Downstream Products

• 1349221-71-1 C₂₂H₂₃F₃N₄O₄S 
• 1374744-71-4 N-[4-(5-p-tolyl-3-trifluoromethyl-pyrazol-1-yl)-phenyl]-aminosulfonamide 
• 169590-42-5 4-[5-(4-(methyl)phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulphonamide 
• 365530-13-8 4-[5-(4-methylphenyl)-3-trifluoromethyl-1H-pyrazol-1-yl]aniline 

Relevant articles and documents

Development of celecoxib-derived antifungals for crop protection

Selective COX-2 inhibitor celecoxib was found directly inhibiting the growth of tested phytopathogenic fungi with the inhibitory rate ranging from 30 to 40% at 100 μg/ml. Lead optimization of celecoxib led to the identification of compound 12 among its derivatives as the most active antifungal candidate. The antifungal effect of compound 12 was supposed to be independent of COX-2 inhibition. Transcriptome profiling analysis of Fusarium graminearium (PH-1) treated with compound 12 brought about 406 up-regulated and 572 down-regulated differentially express genes (DEGs) respectively.

Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA.